H. R. 6—233 
‘‘(C) representatives from other entities as designated 
by the Director. 
‘‘(4) MEETINGS.—The members of the Emerging Threats 
Committee shall meet, in person and not through any delegate 
or representative, not less frequently than once per calendar 
year, before June 1. At the call of the Director or the Chair-
person, the Emerging Threats Committee may hold additional 
meetings as the members may choose. 
‘‘(5) CONTRACT, AGREEMENT, AND OTHER AUTHORITY.—The 
Director may award contracts, enter into interagency agree-
ments, manage individual projects, and conduct other activities 
in support of the identification of emerging drug threats and 
in support of the development, implementation, and assessment 
of any Emerging Threat Response Plan. 
‘‘(6) CRITERIA TO IDENTIFY EMERGING DRUG THREATS.—Not 
later than 180 days after the date on which the Committee 
first meets, the Committee shall develop and recommend to 
the Director criteria to be used to identify an emerging drug 
threat or the termination of an emerging drug threat designa-
tion based on information gathered by the Committee, statis-
tical data, and other evidence. 
‘‘(c) DESIGNATION.— 
‘‘(1) IN GENERAL.—The Director, in consultation with the 
Coordinator, the Committee, and the head of each National 
Drug Control Program Agency, may designate an emerging 
drug threat in the United States. 
‘‘(2) STANDARDS FOR DESIGNATION.—The Director, in con-
sultation with the Coordinator, shall promulgate and make 
publicly available standards by which a designation under para-
graph (1) and the termination of such designation may be 
made. In developing such standards, the Director shall consider 
the recommendations of the committee and other criteria the 
Director considers to be appropriate. 
‘‘(3) PUBLIC STATEMENT REQUIRED.—The Director shall pub-
lish a public written statement on the portal of the Office 
explaining the designation of an emerging drug threat or the 
termination of such designation and shall notify the appropriate 
congressional committees of the availability of such statement 
when a designation or termination of such designation has 
been made. 
‘‘(d) PLAN.— 
‘‘(1) PUBLIC AVAILABILITY OF PLAN.—Not later than 90 days 
after making a designation under subsection (c), the Director 
shall publish and make publicly available an Emerging Threat 
Response Plan and notify the President and the appropriate 
congressional committees of such plan’s availability. 
‘‘(2) TIMING.—Concurrently with the annual submissions 
under section 706(g), the Director shall update the plan and 
report on implementation of the plan, until the Director issues 
the public statement required under subsection (c)(3) to termi-
nate the emerging drug threat designation. 
‘‘(3) CONTENTS OF AN EMERGING THREAT RESPONSE PLAN.— 
The Director shall include in the plan required under this 
subsection— 
‘‘(A) a comprehensive strategic assessment of the 
emerging drug threat, including the current availability
H. R. 6—234 
of, demand for, and effectiveness of evidence-based preven-
tion, treatment, and enforcement programs and efforts to 
respond to the emerging drug threat; 
‘‘(B) comprehensive, research-based, short- and long- 
term, quantifiable goals for addressing the emerging drug 
threat, including for reducing the supply of the drug des-
ignated as the emerging drug threat and for expanding 
the availability and effectiveness of evidence-based sub-
stance use disorder treatment and prevention programs 
to reduce the demand for the emerging drug threat; 
‘‘(C) performance measures pertaining to the plan’s 
goals, including quantifiable and measurable objectives and 
specific targets; 
‘‘(D) the level of funding needed to implement the 
plan, including whether funding is available to be 
reprogrammed or transferred to support implementation 
of the plan or whether additional appropriations are nec-
essary to implement the plan; 
‘‘(E) an implementation strategy for the media cam-
paign under subsection (f), including goals as described 
under subparagraph (B) of this paragraph and performance 
measures, objectives, and targets, as described under 
subparagraph (C) of this paragraph; and 
‘‘(F) any other information necessary to inform the 
public of the status, progress, or response of an emerging 
drug threat. 
‘‘(4) IMPLEMENTATION.— 
‘‘(A) IN GENERAL.—Not later than 120 days after the 
date on which a designation is made under subsection 
(c), the Director, in consultation with the President, the 
appropriate congressional committees, and the head of each 
National Drug Control Program Agency, shall issue guid-
ance on implementation of the plan described in this sub-
section to the National Drug Control Program Agencies 
and any other relevant agency determined to be necessary 
by the Director. 
‘‘(B) COORDINATOR’S
RESPONSIBILITIES.—The Coordi-
nator shall— 
‘‘(i) direct the implementation of the plan among 
the agencies identified in the plan, State, local, and 
Tribal governments, and other relevant entities; 
‘‘(ii) facilitate information-sharing between agen-
cies identified in the plan, State, local, and Tribal 
governments, and other relevant entities; and 
‘‘(iii) monitor implementation of the plan by coordi-
nating the development and implementation of collec-
tion and reporting systems to support performance 
measurement and adherence to the plan by agencies 
identified in plan, where appropriate. 
‘‘(C) REPORTING.—Not later than 180 days after the 
date on which a designation is made under subsection 
(c) and in accordance with subparagraph (A), the head 
of each agency identified in the plan shall submit to the 
Coordinator a report on implementation of the plan. 
‘‘(e) EVALUATION OF MEDIA CAMPAIGN.—Upon designation of 
an emerging drug threat, the Director shall evaluate whether a 
media campaign would be appropriate to address that threat.
H. R. 6—235 
‘‘(f) NATIONAL ANTI-DRUG MEDIA CAMPAIGN.— 
‘‘(1) IN GENERAL.—The Director shall, to the extent feasible 
and appropriate, conduct a national anti-drug media campaign 
(referred to in this subtitle as the ‘national media campaign’) 
in accordance with this subsection for the purposes of— 
‘‘(A) preventing substance abuse among people in the 
United States; 
‘‘(B) educating the public about the dangers and nega-
tive consequences of substance use and abuse, including 
patient and family education about the characteristics and 
hazards of substance abuse and methods to safeguard 
against substance use, to include the safe disposal of 
prescription medications; 
‘‘(C) supporting evidence-based prevention programs 
targeting the attitudes, perception, and beliefs of persons 
concerning substance use and intentions to initiate or con-
tinue such use; 
‘‘(D) encouraging individuals affected by substance use 
disorders to seek treatment and providing such individuals 
with information on— 
‘‘(i) how to recognize addiction issues; 
‘‘(ii) what forms of evidence-based treatment 
options are available; and 
‘‘(iii) how to access such treatment; 
‘‘(E) combating the stigma of addiction and substance 
use disorders, including the stigma of treating such dis-
orders with medication-assisted treatment therapies; and 
‘‘(F) informing the public about the dangers of any 
drug identified by the Director as an emerging drug threat 
as appropriate. 
‘‘(2) USE OF FUNDS.— 
‘‘(A) IN GENERAL.—Amounts made available to carry 
out this subsection for the national media campaign may 
only be used for the following: 
‘‘(i) The purchase of media time and space, 
including the strategic planning for, tracking, and 
accounting of, such purchases. 
‘‘(ii) Creative and talent costs, consistent with 
subparagraph (B)(i). 
‘‘(iii) Advertising production costs, which may 
include television, radio, internet, social media, and 
other commercial marketing venues. 
‘‘(iv) Testing and evaluation of advertising. 
‘‘(v) Evaluation of the effectiveness of the national 
media campaign. 
‘‘(vi) Costs of contracts to carry out activities 
authorized by this subsection. 
‘‘(vii) Partnerships with professional and civic 
groups, 
community-based 
organizations, 
including 
faith-based organizations, and government organiza-
tions related to the national media campaign. 
‘‘(viii) Entertainment industry outreach, inter-
active outreach, media projects and activities, public 
information, news media outreach, and corporate 
sponsorship and participation. 
‘‘(ix) Operational and management expenses. 
‘‘(B) SPECIFIC REQUIREMENTS.—
H. R. 6—236 
‘‘(i) CREATIVE SERVICES.—In using amounts for cre-
ative and talent costs under subparagraph (A)(ii), the 
Director shall use creative services donated at no cost 
to the Government wherever feasible and may only 
procure creative services for advertising— 
‘‘(I) responding to high-priority or emergent 
campaign needs that cannot timely be obtained 
at no cost; or 
‘‘(II) intended to reach a minority, ethnic, or 
other special audience that cannot reasonably be 
obtained at no cost. 
‘‘(ii) TESTING AND EVALUATION OF ADVERTISING.— 
In using amounts for testing and evaluation of adver-
tising under subparagraph (A)(iv), the Director shall 
test all advertisements prior to use in the national 
media campaign to ensure that the advertisements 
are effective with the target audience and meet 
industry-accepted standards. The Director may waive 
this requirement for advertisements using no more 
than 10 percent of the purchase of advertising time 
purchased under this subsection in a fiscal year and 
no more than 10 percent of the advertising space pur-
chased under this subsection in a fiscal year, if the 
advertisements respond to emergent and time-sensitive 
campaign needs or the advertisements will not be 
widely utilized in the national media campaign. 
‘‘(iii) CONSULTATION.—For the planning of the cam-
paign under paragraph (1), the Director may consult 
with— 
‘‘(I) the head of any appropriate National Drug 
Control Program Agency; 
‘‘(II) experts on the designated drug; 
‘‘(III) State, local, and Tribal government offi-
cials and relevant agencies; 
‘‘(IV) communications professionals; 
‘‘(V) the public; and 
‘‘(VI) appropriate congressional committees. 
‘‘(iv) EVALUATION OF EFFECTIVENESS OF NATIONAL 
MEDIA CAMPAIGN.—In using amounts for the evaluation 
of the effectiveness of the national media campaign 
under subparagraph (A)(v), the Director shall— 
‘‘(I) designate an independent entity to 
evaluate by April 20 of each year the effectiveness 
of the national media campaign based on data 
from— 
‘‘(aa) the Monitoring the Future Study 
published by the Department of Health and 
Human Services; 
‘‘(bb) the National Survey on Drug Use 
and Health; and 
‘‘(cc) other relevant studies or publica-
tions, as determined by the Director, including 
tracking 
and 
evaluation 
data 
collected 
according 
to 
marketing 
and 
advertising 
industry standards; and 
‘‘(II) ensure that the effectiveness of the 
national media campaign is evaluated in a manner